• Thermo Fisher set out its shareholder meeting agenda, with votes scheduled on director elections, an advisory vote on executive compensation, and ratification of the independent auditors for 2026.
• The presentation highlighted a $45 billion revenue base, more than 125,000 colleagues, and $1.4 billion in R&D investment.
• It outlined segment revenue of $24.4 billion for Laboratory Products & Biopharma Services, $10.7 billion for Life Sciences Solutions, $7.6 billion for Analytical Instruments, and $4.7 billion for Specialty Diagnostics.
• It also flagged a long-term revenue mix weighted to pharma and biotech at 57%, with services and consumables at 84% of sales.
• Management emphasized continued execution through its Practical Process Improvement business system, with a focus on productivity, customer allegiance, and quality.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Thermo Fisher Scientific Inc. published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.